AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3285763 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg)
Number of subjects: 16
Study 3285763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29689025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab + subthreshold micropulse laser photocoagulation (IVR + SMLP)
Number of subjects: 46
Study 29689025 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) monotherapy
Number of subjects: 46
Study 28035912 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound with thumb spica splint
Number of subjects: 30
Study 28035912 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ultrasound alone
Number of subjects: 30
Study 26168752 — intervention group
Group type: EXPERIMENTAL
Intervention: RO (external ring opened, hernial sac twisted and doubly ligated)
Number of subjects: 428
Study 26168752 — intervention group
Group type: EXPERIMENTAL
Intervention: ST (hernial sac twisted and doubly ligated without opening the ring)
Number of subjects: 428
Study 26168752 — intervention group
Group type: EXPERIMENTAL
Intervention: DL (double ligation of hernial sac without ring opening nor twisted)
Number of subjects: 428
Study 26168752 — intervention group
Group type: COMPARATOR
Intervention: SL (single ligation of hernial sac with neither ring opening nor sac twisting)
Number of subjects: 428
Study 23892902 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-bout group (30 min × 1) 3 d per week
Number of subjects: 23
Study 23892902 — intervention group
Group type: COMPARATOR
Intervention: Short-bouts group (10 min × 3) 3 d per week
Number of subjects: 23
Study 22049798 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 30 days
Number of subjects: 80
Study 22049798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18497524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 73
Study 18497524 — intervention group
Group type: COMPARATOR
Intervention: Travoprost
Number of subjects: 73
Study 16527402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline health-state-related variables
Number of subjects: 148
Study 16527402 — intervention group
Group type: COMPARATOR
Intervention: Patients without disability
Number of subjects: 148
Study 16527402 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors identified
Number of subjects: 148
Study 16527402 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of baseline health-state-related measures with post-treatment measures
Number of subjects: 148
Study 14527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-driven care
Number of subjects: 172
Study 14527106 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study 10908079 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 56
Study 10908079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8612391 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 12
Study 8612391 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg moclobemide
Number of subjects: 12
Study 8612391 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of entacapone and moclobemide
Number of subjects: 12
Study 8612391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8612391 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 12
Study 8612391 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone and moclobemide (combined)
Number of subjects: 12
Study 1599113 — intervention group
Group type: COMPARATOR
Intervention: 1% methohexital in saline
Number of subjects: 24
Study 1599113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methohexital in lipid emulsion
Number of subjects: 24
Study 1599113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% methohexital in saline
Number of subjects: 24
Study 6443775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefsulodin
Number of subjects: 67
Study 6443775 — intervention group
Group type: COMPARATOR
Intervention: Reference antibiotics (gentamicin, tobramycin, amikacin, or ticarcillin)
Number of subjects: 67
Study 6443775 — intervention group
Group type: COMPARATOR
Intervention: Reference antibiotics
Number of subjects: 67
Study 6443775 — intervention group
Group type: COMPARATOR
Intervention: Cefsulodin or reference antibiotics
Number of subjects: 67
Study 31913519 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 1230
Study 31913519 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg
Number of subjects: 1230
Study 31913519 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1230
Study 30029719 — intervention group
Group type: COMPARATOR
Intervention: Localized heat
Number of subjects: 39
Study 30029719 — intervention group
Group type: COMPARATOR
Intervention: Oral hydration
Number of subjects: 39
Study 30029719 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 39
Study 27170538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with cycle ergometer
Number of subjects: 34
Study 27170538 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 34
Study 25630248 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Resistance (MR)
Number of subjects: 30
Study 25630248 — intervention group
Group type: EXPERIMENTAL
Intervention: High Resistance (HR)
Number of subjects: 30
Study 25630248 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 23047792 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review program
Number of subjects: 80
Study 21415134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antithrombotic therapy (subcutaneous idraparinux 2.5 mg weekly + antiplatelet therapy)
Number of subjects: 4576
Study 21415134 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation therapy only (dose-adjusted vitamin K antagonists)
Number of subjects: 4576
Study 21415134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antithrombotic therapy
Number of subjects: 4576
Study 18502255 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation (suberythemal doses, twice weekly for 12 weeks)
Number of subjects: 51
Study 18502255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UV irradiation)
Number of subjects: 51
Study 16553686 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized exercise programme (12-month programme of cardiorespiratory, stretching, muscle-strengthening and relaxation exercises, 2 sessions per week, total of 3 hours weekly)
Number of subjects: 48
Study 16553686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 15220882 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self‐training program
Number of subjects: 60
Study 15220882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Number of subjects: 60
Study 15220882 — intervention group
Group type: COMPARATOR
Intervention: Functional brace
Number of subjects: 60
Study 11061158 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of an outpatient practice guideline
Number of subjects: 0
Study 12206032 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Optimized Stannous Fluoride (COSF) dentifrice
Number of subjects: 0
Study 12206032 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 0
Study 8446047 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 26
Study 8446047 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric glucose infusion
Number of subjects: 26
Study 3097383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 100 micrograms of human corticotropin-releasing factor
Number of subjects: 12
Study 3097383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31613387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance-exercise intervention (DI)
Number of subjects: 62
Study 31613387 — intervention group
Group type: COMPARATOR
Intervention: Life as usual (LAU)
Number of subjects: 62
Study 29423501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily) and Erlotinib (75 mg daily)
Number of subjects: 92
Study 29423501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 26787029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-centistoke silicone oil
Number of subjects: 85
Study 26787029 — intervention group
Group type: COMPARATOR
Intervention: 5000-centistoke silicone oil
Number of subjects: 85
Study 24057928 — intervention group
Group type: EXPERIMENTAL
Intervention: SEQ-FLUOX (fluoxetine 20mg, starting 8 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Number of subjects: 216
Study 24057928 — intervention group
Group type: COMPARATOR
Intervention: ST-FLUOX (fluoxetine 20mg, starting 2 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Number of subjects: 216
Study 24057928 — intervention group
Group type: EXPERIMENTAL
Intervention: SEQ-FLUOX
Number of subjects: 216
Study 22993923 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 120
Study 22993923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anaesthesia (general + epidural)
Number of subjects: 120
Study 22993923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anaesthesia (general + spinal)
Number of subjects: 120
Study 20013016 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin therapy
Number of subjects: 1070
Study 18595990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 400 mug of cobalamin
Number of subjects: 107
Study 18595990 — intervention group
Group type: COMPARATOR
Intervention: No intervention (placebo)
Number of subjects: 107
Study 16021395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early chest tube removal
Number of subjects: 93
Study 16021395 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest tube management
Number of subjects: 93
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (vincristine, actinomycin-D, cyclophosphamide - VAC)
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus radiotherapy (RT)
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy plus RT
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy without RT
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-III/IV treatments
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-I/II treatments
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 1-9 years at diagnosis
Number of subjects: 151
Study 11413538 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy (surgery and RT)
Number of subjects: 151
Study 9001297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 microg every 12 h
Number of subjects: 15
Study 9001297 — intervention group
Group type: COMPARATOR
Intervention: Oral theophylline (individually dose‐titrated sustained-release)
Number of subjects: 15
Study 8394627 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (0.5 g b.i.d.)
Number of subjects: 34
Study 8394627 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (0.4 g b.i.d.)
Number of subjects: 34
Study 8394627 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 34
Study 3318859 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthaderm
Number of subjects: 0
Study 3318859 — intervention group
Group type: COMPARATOR
Intervention: Control (non-adhesive dressing)
Number of subjects: 0
Study 31325318 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics treatment
Number of subjects: 515
Study 26583455 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal training (HRT)
Number of subjects: 21
Study 26583455 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 21
Study 27118206 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of daily GH dose (IGF-1 target level of 1 to 2 SDS)
Number of subjects: 32
Study 27118206 — intervention group
Group type: COMPARATOR
Intervention: Decrease of daily GH dose (IGF-1 target level of -2 to -1 SDS)
Number of subjects: 32
Study 24267731 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day
Number of subjects: 96
Study 24267731 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg/day
Number of subjects: 96
Study 22403987 — intervention group
Group type: COMPARATOR
Intervention: Positive control toothpaste containing 8.0% arginine and 1450 ppm fluoride as sodium monofluorophosphate (MFP) in a calcium carbonate base
Number of subjects: 150
Study 22403987 — intervention group
Group type: COMPARATOR
Intervention: Positive control toothpaste containing 8.0% arginine and 1450 ppm fluoride as MFP in a calcium carbonate base
Number of subjects: 150
Study 22403987 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 8% strontium acetate and 1040 ppm fluoride as NaF in a silica base
Number of subjects: 150
Study 22403987 — intervention group
Group type: COMPARATOR
Intervention: Negative control toothpaste containing 1100 ppm fluoride as NaF in a silica base
Number of subjects: 150
Study 19298639 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of darbepoetin alfa
Number of subjects: 65
Study 19298639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of darbepoetin alfa
Number of subjects: 65
Study 19298639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both s.c. and i.v. administration of darbepoetin alfa
Number of subjects: 65
Study 16808591 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (3M ESPE, Seefeld, Germany)
Number of subjects: 40
Study 16808591 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT (3M Unitex, Monrovia, Calif)
Number of subjects: 40
Study 14688694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic filtration
Number of subjects: 582
Study 14688694 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 582
Study 11055816 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded locomotion (walking)
Number of subjects: 8
Study 11055816 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded locomotion (steering a wheelchair)
Number of subjects: 8
Study 11055816 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded locomotion (verbal ordering a second person pushing their wheelchair)
Number of subjects: 8
Study 11055816 — intervention group
Group type: COMPARATOR
Intervention: Control group (experts in other non-gymnastic sports)
Number of subjects: 8
Study 9242894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 12
Study 9242894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8392826 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron tablet (2 mg)
Number of subjects: 85
Study 8392826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 3107546 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin therapy (1 to 8 mg/day for 8 weeks)
Number of subjects: 20
Study 3107546 — intervention group
Group type: COMPARATOR
Intervention: Propranolol therapy (20 to 240 mg/day for 8 weeks)
Number of subjects: 20
Study 29220885 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol‐epoetin β (MEB)
Number of subjects: 208
Study 29220885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with disease‐modifying drugs and MEB
Number of subjects: 208
Study 29220885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy using MEB medication and iron
Number of subjects: 208
Study 26969836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lettuce juice beverage containing approximately 200 mg nitrate per day (test)
Number of subjects: 44
Study 26969836 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage devoid of nitrate (control)
Number of subjects: 44
Study 25621588 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-forgiveness workbook intervention (6-hour self-directed workbook)
Number of subjects: 204
Study 25621588 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 204
Study 23041328 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time optical biopsy analysis of polyps with narrow band imaging (NBI)
Number of subjects: 12
Study 20627979 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 IU starting dose of recombinant FSH (r‐FSH)
Number of subjects: 32
Study 20627979 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU starting dose of recombinant FSH (r‐FSH)
Number of subjects: 32
Study 19120955 — intervention group
Group type: EXPERIMENTAL
Intervention: New rating form with prompts, free-text comments, behavioral anchors, and fewer scoring levels
Number of subjects: 80
Study 19120955 — intervention group
Group type: COMPARATOR
Intervention: Current American Board of Internal Medicine Mini-CEX form
Number of subjects: 80
Study 21775910 — intervention group
Group type: EXPERIMENTAL
Intervention: 530 mg of concentrated valerian extract twice a day for 4 weeks
Number of subjects: 100
Study 21775910 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day for 4 weeks
Number of subjects: 100
Study 16238858 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (reading about symptoms and consequences of frostbite)
Number of subjects: 121
Study 16238858 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassurance condition (reading about the safety of the CPT)
Number of subjects: 121
Study 16238858 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no orienting passage)
Number of subjects: 121
Study 16238858 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition
Number of subjects: 121
Study 12898824 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies among patients with allergic diseases
Number of subjects: 0
Study 9855317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions (PZA 30 mg/kg)
Number of subjects: 14
Study 9855317 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids (PZA 30 mg/kg)
Number of subjects: 14
Study 9855317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (PZA 30 mg/kg)
Number of subjects: 14
Study 7978423 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (A)
Number of subjects: 60
Study 7978423 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (V)
Number of subjects: 60
Study 7978423 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium (M)
Number of subjects: 60
Study 7978423 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium with Mivacurium (cAM)
Number of subjects: 60
Study 7978423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with Mivacurium (cVM)
Number of subjects: 60
Study 7978423 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 60
Study 3289717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2.4 mg average daily dose)
Number of subjects: 130
Study 3289717 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline hydrochloride (135 mg average daily dose)
Number of subjects: 130
Study 3289717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 130
Study 30115104 — intervention group
Group type: EXPERIMENTAL
Intervention: At-the-margins analysis
Number of subjects: 2252
Study 30115104 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-the-table analysis
Number of subjects: 2252
Study 30115104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian vetted bootstrap
Number of subjects: 2252
Study 27632863 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS) program performed 3 times weekly for 4 weeks
Number of subjects: 24
Study 27632863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 26202165 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (BIS 40 < BIS ≤ 50)
Number of subjects: 192
Study 26202165 — intervention group
Group type: COMPARATOR
Intervention: Group I (BIS 30 < BIS ≤ 40)
Number of subjects: 192
Study 26202165 — intervention group
Group type: COMPARATOR
Intervention: Group III (BIS 50 < BIS ≤ 60)
Number of subjects: 192
Study 23041618 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Changes (SC) approach
Number of subjects: 481
Study 23041618 — intervention group
Group type: EXPERIMENTAL
Intervention: SC phone
Number of subjects: 481
Study 23041618 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 481
Study 20939080 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs3943552 T allele in the GLI2 gene
Number of subjects: 327
Study 18979972 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week smoking cessation program with optimistic expectations
Number of subjects: 0
Study 18979972 — intervention group
Group type: COMPARATOR
Intervention: 8-week smoking cessation program with modest expectations
Number of subjects: 0
Study 18979972 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week smoking cessation program
Number of subjects: 0
Study 16303228 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-and-treat program for vaginal infection
Number of subjects: 2058
Study 16303228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screen-and-treat program)
Number of subjects: 2058
Study 12660517 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from cyclosporine A (CsA) to azathioprine (AZA)
Number of subjects: 29
Study 12660517 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from cyclosporine A (CsA) to mycophenolate mofetil (MMF)
Number of subjects: 29
Study 12660517 — intervention group
Group type: COMPARATOR
Intervention: Control group without AR
Number of subjects: 29
Study 12660517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) therapy
Number of subjects: 29